Winduet 2 Tablet PR is a combination oral antihyperglycemic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The combined action of these agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled with diet, exercise, or monotherapy. Winduet 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or known hypersensitivity to its components. Caution is advised in patients with hepatic dysfunction, cardiovascular disease, or conditions predisposing to hypoxia. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea, vomiting, and diarrhea, and rare cases of lactic acidosis associated with metformin. Regular monitoring of blood glucose levels, renal function, and liver enzymes is recommended during therapy to optimize efficacy and safety.